Securian Asset Management Inc. Has $1.78 Million Stock Holdings in DexCom, Inc. $DXCM

Securian Asset Management Inc. lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,350 shares of the medical device company’s stock after selling 253 shares during the quarter. Securian Asset Management Inc.’s holdings in DexCom were worth $1,776,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC lifted its holdings in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in DexCom during the 1st quarter valued at about $27,000. Anderson Financial Strategies LLC bought a new position in DexCom during the 1st quarter valued at about $37,000. Alpine Bank Wealth Management bought a new position in DexCom during the 1st quarter valued at about $40,000. Finally, Private Trust Co. NA lifted its holdings in DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 335 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Up 1.4%

DexCom stock opened at $70.70 on Thursday. The company’s 50 day simple moving average is $72.76 and its 200 day simple moving average is $77.65. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm has a market capitalization of $27.73 billion, a price-to-earnings ratio of 49.10, a PEG ratio of 1.46 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm earned $0.43 EPS. DexCom’s quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity

In related news, Director Kyle Malady sold 667 shares of DexCom stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,849 shares of company stock worth $564,733 over the last quarter. 0.32% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have weighed in on DXCM. Raymond James Financial raised their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 31st. Robert W. Baird lowered their price objective on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a research report on Friday, September 26th. Morgan Stanley raised their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Canaccord Genuity Group restated a “buy” rating and issued a $106.00 price objective on shares of DexCom in a research report on Monday, September 29th. Finally, Argus began coverage on shares of DexCom in a research report on Thursday, August 21st. They issued a “buy” rating and a $100.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $96.40.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.